Literature DB >> 33457311

Why multisystem inflammatory syndrome in children has been less commonly described in Asia?

Weiguo Li1,2,3, Yuyi Tang1,2,3, Yuan Shi1,2,3, Yaolong Chen4,5,6, Enmei Liu1,2,3.   

Abstract

Entities:  

Year:  2020        PMID: 33457311      PMCID: PMC7804475          DOI: 10.21037/tp-20-151

Source DB:  PubMed          Journal:  Transl Pediatr        ISSN: 2224-4336


× No keyword cloud information.
Recently, pediatricians from Europe and North America have found that increasing cases of multisystem inflammatory syndrome in children (MIS-C) may be associated with SARS-CoV-2 infection (1-3). It is quite confusing that in Asia where Coronavirus Disease 2019 (COVID-19) first outbroke, cases of MIS-C have been less commonly described. Various speculations have then emerged on this issue, and some even suspected that Asian pediatricians missed the diagnosis of MIS-C in the early epidemic, yet we hold different viewpoints on this issue. In the early epidemic when the published data on COVID-19 in children were limited, most case reports originated from Asia (mainly from China, ). As early as February 2020, Chinese pediatricians reported the first severe COVID-19 case in children in the world. The patient had prominent gastrointestinal symptoms at onset and rapidly progressed to shock, acute respiratory distress syndrome (ARDS), and kidney failure. We now consider it a suspicious case of MIS-C as the patient had multiple organs involvement (4). Another case series included 171 confirmed cases of children with SARS-CoV-2 infection and only 3 of them required intensive care support and invasive mechanical ventilation (5). All these 3 patients had coexisting conditions and one 10-month-old child died with multiorgan failure. Also, the largest case series on children with COVID-19 was published from China, disclosing detailed symptoms and outcomes of the confirmed cases (6). However, limited number of clustered cases were not enough to conclude the connection with MIS-C. We therefore postulated about the reasons why MIS-C has been less commonly described in Asia.
Figure 1

Types of published articles on children with Coronavirus Disease 2019 (COVID-19) (n=249). Data based on our PubMed search from its inception to May 22, 2020 (The details of the search strategy can be found in Appendix 1). It indicated that at the onset of the outbreak, most case reports were from Asia.

Types of published articles on children with Coronavirus Disease 2019 (COVID-19) (n=249). Data based on our PubMed search from its inception to May 22, 2020 (The details of the search strategy can be found in Appendix 1). It indicated that at the onset of the outbreak, most case reports were from Asia. Firstly, it is probably related to the different prevalence rates of COVID-19. Wuhan, the worst affected city by SARS-CoV-2 in China, has an infection rate of around 0.6% and a fatality rate of 7.7%, which was much lower than that of the main European epidemic cities, where the infection rate reached up to 9% (Bergamo, Italy, gathering site of MIS-C cases) and the fatality rate was close to 20% widely. Children cases may account for less than 2% of all cases all over the world, and the association might be found only when the prevalence rate was relatively high. Besides, differences in ethnic or genetic background and SARS-CoV-2 subtypes may lead to different COVID-19 prevalence and incidence of MIS-C, but the relationship between ethnicity and susceptibility of MIS-C was inconclusive. Despite cohorts from Europe and North America have showed high proportion of children of black origin, there were certain amounts of Asian patients (2). During the COVID-19 pandemic, hospitals in China conducted large-scale SARS-CoV-2 screening for patients with fever, especially for those with severe illness. Other Asian countries were likely to have adopted the same strategy, which would be an essential opportunity for catching COVID-19 related syndromes. However, no clustered MIS-C cases like those in the Italian pediatric intensive care unit (PICU) were observed. MIS-C presents with symptoms similar to Kawasaki disease (KD), which is first detected and named in Japan (7). Moreover, as the country with the highest incidence of reported KD in children, Japan is a candidate country to identify the association between SARS-CoV-2 infection and MIS-C. A possible association between the coronavirus infection and KD was first reported as long ago as 2005 in New Haven, USA (8). In order to prove the hypothesis again, Japanese researchers performed multiple studies but unfortunately failed to confirm it. In addition, Tokyo, the worst affected city in Japan, has an infection rate of only 0.1% and a case fatality rate of 4.4%. As a reportable disease in Japan, KD or related syndromes are surveilled by their health care system, and these data will add more evidence for the association. The possible association between MIS-C and SARS-CoV-2 infection is a rather potential risk for children. As advocated by WHO, pediatricians around the world should strengthen the surveillance of MIS-C during the COVID-19 pandemic (9). Serological and PCR tests for SARS-CoV-2 should be carried out in suspected MIS-C cases, and those children should also be recruited in regional or international clinical researches, like the DIAMONDS study funded by Europe Union. At present, we are facing a challenging problem, that is, understanding how SARS-CoV-2 infection affects the immune system, which is critical for the development of vaccines and drugs, as well as the prediction of the risk of vaccine side effects. It’s worth mentioning that recently we have conducted a guideline for COVID-19 in children, which recommends against using intravenous immunoglobulin (IVIG) to treat children with severe COVID-19 (10). We may now need to re-evaluate the evidence and update our recommendation on IVIG, taking into consideration that more and more children are being affected by MIS-C. The article’s supplementary files as
  9 in total

1.  [First case of severe childhood novel coronavirus pneumonia in China].

Authors:  F Chen; Z S Liu; F R Zhang; R H Xiong; Y Chen; X F Cheng; W Y Wang; J Ren
Journal:  Zhonghua Er Ke Za Zhi       Date:  2020-02-11

2.  [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children].

Authors:  T Kawasaki
Journal:  Arerugi       Date:  1967-03

3.  Epidemiology of COVID-19 Among Children in China.

Authors:  Yuanyuan Dong; Xi Mo; Yabin Hu; Xin Qi; Fan Jiang; Zhongyi Jiang; Shilu Tong
Journal:  Pediatrics       Date:  2020-03-16       Impact factor: 7.124

4.  Association between a novel human coronavirus and Kawasaki disease.

Authors:  Frank Esper; Eugene D Shapiro; Carla Weibel; David Ferguson; Marie L Landry; Jeffrey S Kahn
Journal:  J Infect Dis       Date:  2005-01-14       Impact factor: 5.226

5.  An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study.

Authors:  Lucio Verdoni; Angelo Mazza; Annalisa Gervasoni; Laura Martelli; Maurizio Ruggeri; Matteo Ciuffreda; Ezio Bonanomi; Lorenzo D'Antiga
Journal:  Lancet       Date:  2020-05-13       Impact factor: 79.321

6.  Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study.

Authors:  Olivia V Swann; Karl A Holden; Lance Turtle; Louisa Pollock; Cameron J Fairfield; Thomas M Drake; Sohan Seth; Conor Egan; Hayley E Hardwick; Sophie Halpin; Michelle Girvan; Chloe Donohue; Mark Pritchard; Latifa B Patel; Shamez Ladhani; Louise Sigfrid; Ian P Sinha; Piero L Olliaro; Jonathan S Nguyen-Van-Tam; Peter W Horby; Laura Merson; Gail Carson; Jake Dunning; Peter J M Openshaw; J Kenneth Baillie; Ewen M Harrison; Annemarie B Docherty; Malcolm G Semple
Journal:  BMJ       Date:  2020-08-27

7.  SARS-CoV-2 Infection in Children.

Authors:  Xiaoxia Lu; Liqiong Zhang; Hui Du; Jingjing Zhang; Yuan Y Li; Jingyu Qu; Wenxin Zhang; Youjie Wang; Shuangshuang Bao; Ying Li; Chuansha Wu; Hongxiu Liu; Di Liu; Jianbo Shao; Xuehua Peng; Yonghong Yang; Zhisheng Liu; Yun Xiang; Furong Zhang; Rona M Silva; Kent E Pinkerton; Kunling Shen; Han Xiao; Shunqing Xu; Gary W K Wong
Journal:  N Engl J Med       Date:  2020-03-18       Impact factor: 91.245

Review 8.  Rapid advice guidelines for management of children with COVID-19.

Authors:  Enmei Liu; Rosalind L Smyth; Zhengxiu Luo; Amir Qaseem; Joseph L Mathew; Quan Lu; Zhou Fu; Xiaodong Zhao; Shunying Zhao; Janne Estill; Edwin Shih-Yen Chan; Lei Liu; Yuan Qian; Hongmei Xu; Qi Wang; Toshio Fukuoka; Xiaoping Luo; Gary Wing-Kin Wong; Junqiang Lei; Detty Nurdiati; Wenwei Tu; Xiaobo Zhang; Xianlan Zheng; Hyeong Sik Ahn; Mengshu Wang; Xiaoyan Dong; Liqun Wu; Myeong Soo Lee; Guobao Li; Shu Yang; Xixi Feng; Ruiqiu Zhao; Xiaoxia Lu; Zhihui He; Shihui Liu; Weiguo Li; Qi Zhou; Luo Ren; Yaolong Chen; Qiu Li
Journal:  Ann Transl Med       Date:  2020-05

9.  Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2.

Authors:  Elizabeth Whittaker; Alasdair Bamford; Julia Kenny; Myrsini Kaforou; Christine E Jones; Priyen Shah; Padmanabhan Ramnarayan; Alain Fraisse; Owen Miller; Patrick Davies; Filip Kucera; Joe Brierley; Marilyn McDougall; Michael Carter; Adriana Tremoulet; Chisato Shimizu; Jethro Herberg; Jane C Burns; Hermione Lyall; Michael Levin
Journal:  JAMA       Date:  2020-07-21       Impact factor: 157.335

  9 in total
  5 in total

1.  Clinical presentation and short-term outcomes of multisystemic inflammatory syndrome in children in Lagos, Nigeria during the COVID-19 pandemic: A case series.

Authors:  Ogochukwu Sokunbi; Yeside Akinbolagbe; Patricia Akintan; Gabriel Oyeleke; Olusola Kusimo; Uchenna Owowo; Eyitayo Olonade; Olajide Ojo; Esieza Ikhazobor; Oluwatosin Amund; Eucharia Ogbuokiri; Mercy Funsho-Adebayo; Oluwatoyin Adeniyi; Chinyere Uzodimma; Moriam Lamina; Adeola Animashaun; Babayemi Osinaike; Ekanem Ekure; Christy Okoromah
Journal:  EClinicalMedicine       Date:  2022-05-27

Review 2.  Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison.

Authors:  Chetan Sharma; Madhusudan Ganigara; Caroline Galeotti; Joseph Burns; Fernando M Berganza; Denise A Hayes; Davinder Singh-Grewal; Suman Bharath; Sujata Sajjan; Jagadeesh Bayry
Journal:  Nat Rev Rheumatol       Date:  2021-10-29       Impact factor: 20.543

Review 3.  Worldwide epidemiology of neuro-coronavirus disease in children: lessons for the next pandemic.

Authors:  Alicia M Alcamo; Jennifer L McGuire; Hari Krishnan Kanthimathinathan; Juan David Roa; Ericka L Fink
Journal:  Curr Opin Pediatr       Date:  2021-12-01       Impact factor: 2.856

4.  Comparison of the clinical characteristics and outcomes of COVID-19 in children before and after the emergence of Delta variant of concern in Japan.

Authors:  Kensuke Shoji; Takayuki Akiyama; Shinya Tsuzuki; Nobuaki Matsunaga; Yusuke Asai; Setsuko Suzuki; Noriko Iwamoto; Takanori Funaki; Norio Ohmagari
Journal:  J Infect Chemother       Date:  2022-01-20       Impact factor: 2.065

5.  Active Surveillance With Seroprevalence-based Infection Rates Indicates Racial Disparities With Pediatric SARS-CoV-2 Requiring Hospitalization in Mississippi, March 2020-February 2021.

Authors:  Charlotte V Hobbs; Sara S Kim; Preeti Vemula; Kengo Inagaki; Virginia A Harrison; Lacy Malloch; Lora M Martin; Gurbaksh Singh; Urita Agana; John M Williams; Kayla Patterson; Theresa Kittle; Paul Byers; April Palmer; Roberto P Santos; Anita Dhanrajani; Meagan Stephenson; Leroy Hung; Phillip Hankins; Nathalie Thornburg; Jan Drobeniuc; Brendan Flannery
Journal:  Pediatr Infect Dis J       Date:  2022-06-07       Impact factor: 3.806

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.